Journal
JOURNAL OF CROHNS & COLITIS
Volume 16, Issue SUPPL 2, Pages -Publisher
OXFORD UNIV PRESS
DOI: 10.1093/ecco-jcc/jjac011
Keywords
Inflammatory bowel diseases; Crohn's disease; ustekinumab; algorithm
Categories
Funding
- AbbVie
Ask authors/readers for more resources
Ustekinumab, a monoclonal antibody targeting IL-12 and IL-23, has shown efficacy and safety in treating moderate to severe Crohn's disease patients, but there is currently no approved therapeutic algorithm.
The treatment of patients with moderate to severe Crohn's disease [CD] is still challenging. Therapeutic options include steroids, immunosuppressants, anti-TNF alpha agents, vedolizumab, and ustekinumab. Ustekinumab is a monoclonal antibody blocking the p40 subunit of IL-12 and IL-23. It showed to be effective and safe in randomised clinical trials and real-life studies and is currently approved for the management of CD patients who are naive to biologics and those who have already been treated with such medications. However, to date, a detailed and approved therapeutic algorithm is not available. The aim of this review is to report the most recent and updated data on the efficacy and safety of ustekinumab for the treatment of patients with moderate to severe CD and to define the optimal management of these patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available